This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cheng, A. Articles by Honkanen, R. E. Search for Related Content PubMed PubMed Citation Articles by Cheng, A. Articles by Honkanen, R. E.

Fostriecin-mediated G₂-M-phase Growth Arrest Correlates with Abnormal Centrosome Replication, the Formation of Aberrant Mitotic Spindles, and the Inhibition of Serine/Threonine Protein Phosphatase Activity¹

Departments of Biochemistry and Molecular Biology [A. C., Z. Z., J. S. K., A. H. W., R. E. H.] and Structural and Cellular Biology [R. B.], College of Medicine, University of South Alabama, Mobile, Alabama 36688

Fostriecin, a structurally unique phosphate ester, is presently under evaluation in clinical trials to determine its potential use as an antitumor drug in humans. Fostriecin has been reported as having inhibitory activity against DNA topoisomerase type II and protein phosphatases implicated in cell-cycle control. However, the relative contribution of these mechanisms to the antitumor activity of fostriecin has not yet been elucidated. In this study, after confirming that fostriecin is a potent inhibitor of serine/threonine protein phosphatase type 2A and a weak inhibitor of serine/threonine protein phosphatase type 1, we show that fostriecin inhibits 50% of the divalent cation independent serine/threonine protein phosphatase (PPase) activity contained in whole cell homogenates of Chinese hamster ovary cells at concentrations associated with antitumor activity (1–20 µM). Investigations into the cellular effects produced by fostriecin treatment reveal that 1–20 µM fostriecin induces a dose-dependent arrest of cell growth during the G₂-M phase of the cell cycle. Immunostaining of treated cells indicates that growth arrest occurs before the completion of mitosis and that fostriecin-induced growth arrest is associated with the aberrant amplification of centrosomes, which results in the formation of abnormal mitotic spindles. The "mitotic block" induced by fostriecin is reversible if treatment is discontinued in <24 h. However, after 24–30 h of continuous treatment, growth arrest is not reversible, and treated cells die even when placed in fostriecin-free media. Correlative studies conducted with established PPase inhibitors reveal that, when applied at concentrations that inhibit PPase activity to a comparable extent, both okadaic acid and cantharidin also induce aberrant centrosome replication, the appearance of multiple aberrant mitotic spindles, and G₂-M-phase growth arrest. These studies add additional support to the concept that PPase inhibition underlies the antitumor activity of fostriecin and suggest that other type-selective PPase inhibitors should be evaluated for potential antitumor activity.

¹ This work was supported by NIH Grant CA 60750 (to R. E. H.) and American Cancer Society Grant CB-151 (to R. B.).

² To whom requests for reprints should be addressed, at Department of Biochemistry and Molecular Biology, MSB 2198, College of Medicine, University of South Alabama, Mobile, AL 36688.

Received 12/29/97. Accepted 6/11/98.

This article has been cited by other articles:

				S. I. Houston, K. J. McManus, M. M. Adams, J. K. Sims, P. B. Carpenter, M. J. Hendzel, and J. C. Rice Catalytic Function of the PR-Set7 Histone H4 Lysine 20 Monomethyltransferase Is Essential for Mitotic Entry and Genomic Stability J. Biol. Chem., July 11, 2008; 283(28): 19478 - 19488. [Abstract] [Full Text] [PDF]

				X. Zhang, Y. Ozawa, H. Lee, Y.-D. Wen, T.-H. Tan, B. E. Wadzinski, and E. Seto Histone deacetylase 3 (HDAC3) activity is regulated by interaction with protein serine/threonine phosphatase 4 Genes & Dev., April 1, 2005; 19(7): 827 - 839. [Abstract] [Full Text] [PDF]

				D. A. Bennin, A. S. A. Don, T. Brake, J. L. McKenzie, H. Rosenbaum, L. Ortiz, A. A. DePaoli-Roach, and M. C. Horne Cyclin G2 Associates with Protein Phosphatase 2A Catalytic and Regulatory B' Subunits in Active Complexes and Induces Nuclear Aberrations and a G1/S Phase Cell Cycle Arrest J. Biol. Chem., July 19, 2002; 277(30): 27449 - 27467. [Abstract] [Full Text] [PDF]

				R. E. Guzman and P. F. Solter Characterization of Sublethal Microcystin-LR Exposure in Mice Vet. Pathol., January 1, 2002; 39(1): 17 - 26. [Abstract] [Full Text] [PDF]

				M. Roberge, B. Cinel, H. J. Anderson, L. Lim, X. Jiang, L. Xu, C. M. Bigg, M. T. Kelly, and R. J. Andersen Cell-based Screen for Antimitotic Agents and Identification of Analogues of Rhizoxin, Eleutherobin, and Paclitaxel in Natural Extracts Cancer Res., September 1, 2000; 60(18): 5052 - 5058. [Abstract] [Full Text]

				S. E. Morgan, R. S. Cadena, S. C. Raimondi, and W. T. Beck Selection of Human Leukemic CEM Cells for Resistance to the DNA Topoisomerase II Catalytic Inhibitor ICRF-187 Results in Increased Levels of Topoisomerase IIalpha and Altered G2/M Checkpoint and Apoptotic Responses Mol. Pharmacol., February 1, 2000; 57(2): 296 - 307. [Abstract] [Full Text]

				A. Cheng, N. M. Dean, and R. E. Honkanen Serine/Threonine Protein Phosphatase Type 1gamma 1 Is Required for the Completion of Cytokinesis in Human A549 Lung Carcinoma Cells J. Biol. Chem., January 21, 2000; 275(3): 1846 - 1854. [Abstract] [Full Text] [PDF]

				A. Cheng, K. E. Ross, P. Kaldis, and M. J. Solomon Dephosphorylation of cyclin-dependent kinases by type 2C protein phosphatases Genes & Dev., November 15, 1999; 13(22): 2946 - 2957. [Abstract] [Full Text]